Response to steroid and immunosuppressive therapies may predict post‐transplant recurrence of steroid‐resistant nephrotic syndrome

• Published in: Pediatric transplantation 2022-12, Vol.26 (8), p.e14103-n/a
• Main Authors: Miura, Kenichiro, Ando, Taro, Kanda, Shoichiro, Hashimoto, Taeko, Kaneko, Naoto, Ishizuka, Kiyonobu, Hamada, Riku, Hataya, Hiroshi, Hotta, Kiyohiko, Gotoh, Yoshimitsu, Nishiyama, Kei, Hamasaki, Yuko, Shishido, Seiichiro, Fujita, Naoya, Hattori, Motoshi
• Format: Article
• Language: English
• Subjects: Genetic screening; genetic testing; Immunosuppressive agents; Kidney diseases; Kidney transplantation; Low density lipoprotein; Nephrotic syndrome; Patients; Plasmapheresis; post‐transplant recurrence; Remission; Risk factors; Rituximab; Steroids; steroid‐resistant nephrotic syndrome; treatment response
• ISSN: 1397-3142; 1399-3046
• DOI: 10.1111/petr.14103

Background Recurrence of SRNS is a major challenge in KT. Several clinical factors, including initial steroid sensitivity, have been associated with increased post‐transplant SRNS recurrence risk. However, conflicting data have been reported, possibly due to the heterogeneous pathophysiology of SRNS and the lack of genetic testing of SRNS patients. Furthermore, the response to immunosuppressive therapies has not been evaluated. Methods Seventy patients aged 1–15 years at SRNS onset who underwent KT between 2002 and 2018 were enrolled. Patients with secondary, familial, syndromic, and genetic forms of SRNS and those who were not treated with steroid were excluded. This study aimed to assess the risk factors for post‐transplant recurrence, including treatment responses to initial steroid therapy and additional therapies with immunosuppressive agents, rituximab, plasmapheresis, and/or LDL‐A. Results Data from 36 kidney transplant recipients were analyzed. Twenty‐two (61%) patients experienced post‐transplant SRNS recurrence, while 14 patients did not. The proportion of patients who achieved complete or partial remission with initial steroid therapy and/or additional therapies with immunosuppressive agents, rituximab, plasmapheresis, and/or LDL‐A was significantly higher in the SRNS recurrence group (19/22, 86%) than in the group without SRNS recurrence (6/14, 43%; p = .01). Conclusion This study suggests that the response to steroid treatment, other immunosuppressive agents, rituximab, plasmapheresis, and/or LDL‐A may predict post‐transplant SRNS recurrence.